Virtual Industry Posters (Non-CE)
Sustained Seizure Freedom with Perampanel 4 mg/day Monotherapy in Patients with Newly Diagnosed/Currently Untreated Recurrent Focal-Onset Seizures, With/Without Focal to Bilateral Tonic-Clonic Seizures: Post Hoc Analysis of Study 342 (FREEDOM)
Authors: Manoj Malhotra, Ji Hyun Kim, Sung Chul Lim, Hirotomo Ninomiya, Takamichi Yamamoto, Anna Patten, Leock Y Ngo, Yuichi Kubota
Sponsored by
Adjunctive Perampanel for Generalized Tonic-Clonic Seizures: Time to Seizure Onset in Phase III Study 332
Authors: Manoj Malhotra, Anna Patten
Sponsored by
What’s Next for Tardive Dyskinesia? Expert Insights from a Cross-Disciplinary Virtual Treatment Panel
Authors:
Chirag Shah, Leslie Lundt, Dawn Vanderhoef, Rif S. El-Mallakh, Amy Belnap, Sanjay Iyer
Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged antipsychotic use. Despite the availability of approved TD medications, diagnosis and treatment can be challenging. We present findings from panel discussions with healthcare professionals who participated in virtual interviews regarding the diagnosis and treatment of TD.
Sponsored by
Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients with Schizophrenia/Schizoaffective Disorder Treated with a VMAT2 Inhibitors
Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with antipsychotic exposure. This real-world study of VMAT2-treated patients was performed to assess the association between patient awareness of TD symptoms and clinician-assessed symptom severity.
Sponsored by
Please forward all questions regarding our posters to medinfo@neurocrine.com.
Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia (TD)
AIMS total score (sum of items 1-7) is usually the primary efficacy measure in TD trials. However, AIMS item 8, which measures global severity of abnormal movements, might be an appropriate assessment in clinical practice. We analyze AIMS item 8 using data from a long-term study of valbenazine.
Sponsored by
Please forward all questions regarding our posters to medinfo@neurocrine.com.
What's Next for Tardive Dyskinesia? Expert Insights from a Cross-Disciplinary Virtual Treatment Panel
Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged antipsychotic use. Despite the availability of approved TD medications, diagnosis and treatment can be challenging. We present findings from panel discussions with healthcare professionals who participated in virtual interviews regarding the diagnosis and treatment of TD.
Sponsored by
Please forward all questions regarding our posters to medinfo@neurocrine.com.
Characteristics of Patients Who Self-Administered Diazepam Nasal Spray for Seizure Clusters: Interim Results From a Phase 3, Open-Label, Repeat-Dose Safety Study
Self-administration of diazepam nasal spray (VALTOCO®) for seizure clusters represents a possible benefit over routes requiring a care partner. Nearly half of surveyed patients self-administering in this phase 3 study reported dosing primarily at the first signs a cluster was coming. This suggests patients took steps to self-control their treatment.
Sponsored by
Effect of Nabiximols Cannabinoid Oromucosal Spray on Spasticity and Muscle Strength in Persons With Multiple Sclerosis Across 3 Randomized Controlled Trials
Sponsored by
Please forward all questions regarding our posters to medinfo@greenwichbiosciences.com.
Safety and Efficacy of Nabiximols in People With Multiple Sclerosis Associated Spasticity: Post Hoc Analyses of a Controlled Enrichment Design Study
Sponsored by
Please forward all questions regarding our posters to medinfo@greenwichbiosciences.com.